Founded in 1999 in Copenhagen, Denmark, we are a dual-listed, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics to fight against cancer and other serious diseases.
An experienced international management team sets the direction for our growth. Our proprietary product pipeline and next-generation antibody technologies result from a strong company culture and passion for innovation. We are rooted in science and inspired by patients.
Combating cancer and other serious diseases through the power of antibodies
Our core purpose summarizes what we strive for – our unstoppable team will improve the lives of patients through innovative and differentiated antibody therapeutics. It supports our vision which captures our aspirations for our future – that by 2030, our knock-your-socks-off “KYSO” antibody medicines are transforming the lives of people with cancer and other serious diseases.
UNLEASHING THE FULL POTENTIAL OF OUR INNOVATIONS
Hear from Genmab’s President and CEO Jan G. J. van de Winkel, Ph.D. how our inspirational 2030 vision came to life. Take a look at the video to learn more.
Our core values
In our quest to turn science into medicine, we use these guideposts to transform the future of cancer treatment:
Passion for innovation
Determination—being the best at what we do
Integrity—we do the right thing
We work as one team and respect each other
Our key accomplishments
Each of our achievements stands as evidence of our unyielding determination, including:
Creators of multiple marketed products*
Inventors of four proprietary technologies
Growing multiple proprietary clinical programs
Pioneers of a robust pre-clinical pipeline
World-class leaders with antibody and R&D expertise
Partners of choice with strategic collaborations
Building and expanding our capabilities with more than 1,500 employees across our four international locations